FOLH1 and prostate carcinoma: Although it is encouraging to see early indications of benefit with the use of PSMA-targeted imaging in guiding treatment of oligometastatic prostate cancer, further evidence regarding efficacy, safety, and quality of life needs to be obtained prior to establishing this approach as the standard of care.